Brief: Passage Bio Reports Updated Interim Data From Uplift-D Study
23/06/2025 12:09
June 23 (Reuters) - Passage Bio Inc PASG.O: PASSAGE BIO REPORTS UPDATED INTERIM DATA FROM UPLIFT-D STUDY AND PROVIDES PROGRAM UPDATE PASSAGE BIO INC - DOSE 1 PBFT02 SHOWS DURABLE INCREASE IN CSF PGRN LEVELS PASSAGE BIO INC -REMAIN ON TRACK TO SEEK REGULATORY FEEDBACK ON FTD-GRN PIVOTAL TRIAL DESIGN IN 1H 2026 Source text: ID:nGNX98q5LK Further company coverage: PASG.O ((Reuters.Briefs@thomsonreuters.com;))